The established and future biomarkers of malignant pleural mesothelioma.
about
Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysisHuman malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.Calretinin as a blood-based biomarker for mesotheliomaExcerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.Advances in treatment of mesothelioma.Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.Mesothelioma from asbestos exposures: Epidemiologic patterns and impact in the United States.Symptom burden in mesothelioma patients admitted to home palliative care.MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.A diagnostically difficult case of a cellular pleural fluid: Morphology, immunohistochemistry, and fluorescence in situ hybridization study.Circulating biomarker for malignant pleural mesothelioma diagnosis: pay attention to study design.Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.Search for biomarkers of asbestos exposure and asbestos-induced cancers in investigations of the immunological effects of asbestos.The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.An Overview of Asbestos and Malignant Pleural Mesothelioma: An Iranian PerspectiveClinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM).Biomarkers in malignant pleural mesothelioma: current status and future directions.Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
P2860
Q26748767-E093C14F-37AE-4D33-B03D-0802B019D283Q27333517-7339BAD5-74CE-4D2C-9225-828A34F5607FQ33556551-C45DEC6F-3DCB-4AB9-8A3F-FD20449451FDQ36385172-DF384347-961C-4222-B6C3-23E5658D0D10Q37349280-CB9487AA-0988-4EB7-A873-87F9FC430789Q37687605-EC292094-8460-49A9-8C4E-86E1088D0D91Q37712647-E2522DEB-3746-45DD-9BAF-D83851AC05BFQ38586323-8DF75445-0713-439F-9B9B-2C71F68BBAA7Q38778106-799DF8EB-0983-4241-A882-672622E70872Q38800916-48BF3ECB-3025-47B0-A597-43EC7B9E9AAAQ38972707-51506A96-EDF4-4AF7-9510-C1CCA8C7DE0FQ38987622-324307D6-6B6C-48D2-8B2E-6CF98F7E9215Q39012195-E3431D82-A9BA-47CF-AB7C-0FE29F8320C3Q39043688-94AC9B4F-67DA-4B0A-A019-C5D34DF1B6AEQ40553595-891E0EC7-D3E6-435B-B752-46B175D6CA8EQ40618919-1C9C2E66-C1D2-44EB-B04F-0831E558EE53Q41025694-0847B28E-7F42-44CA-AB4B-180B88F1CE52Q41272473-A513ABD5-7B91-4975-BA1E-1D66EED42F3FQ42369288-0BD42A43-5B7A-4197-98C4-7D9751EA1A2AQ45824718-2F014A63-67A0-48C7-804C-8E38B3C1FBCBQ46395628-64915EE7-2FF0-477F-8EAA-0D2AD02F4415Q48288890-D1202ECF-6C8D-4BFC-9EB5-504901591E78Q50087832-0AF8780D-F15C-410A-8FC2-375F725E5712Q50102994-890A3CBD-0C56-4859-972A-2BE127D991E2Q52559185-02B8DF83-7C54-4568-8405-9BA55E9CC2A1Q55006991-61EAD9E0-8587-4041-BD9D-0F0729710587Q55647308-901B4C5E-88B7-4893-930A-AF6E3737B6E1
P2860
The established and future biomarkers of malignant pleural mesothelioma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The established and future biomarkers of malignant pleural mesothelioma.
@ast
The established and future biomarkers of malignant pleural mesothelioma.
@en
The established and future biomarkers of malignant pleural mesothelioma.
@nl
type
label
The established and future biomarkers of malignant pleural mesothelioma.
@ast
The established and future biomarkers of malignant pleural mesothelioma.
@en
The established and future biomarkers of malignant pleural mesothelioma.
@nl
prefLabel
The established and future biomarkers of malignant pleural mesothelioma.
@ast
The established and future biomarkers of malignant pleural mesothelioma.
@en
The established and future biomarkers of malignant pleural mesothelioma.
@nl
P2093
P50
P1476
The established and future biomarkers of malignant pleural mesothelioma.
@en
P2093
P304
P356
10.1016/J.CTRV.2015.05.001
P577
2015-05-08T00:00:00Z